Search results
Kansas sues Pfizer over 'misrepresentations' and 'adverse events' of COVID-19 vaccine
FOX Business· 5 days agoThe State of Kansas has filed a lawsuit against Pfizer, Inc. for alleged consumer protection...
Moderna Just Gave Investors Another Reason to Buy the Stock | The Motley Fool
The Motley Fool· 6 days agoModerna (MRNA -3.58%) is best known for its work in the coronavirus vaccine market. Let's look...
25,274 Shares in Moderna, Inc. (NASDAQ:MRNA) Bought by Los Angeles Capital Management LLC
ETF DAILY NEWS· 16 hours agoLos Angeles Capital Management LLC acquired a new position in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) during the 1st quarter, according to its most recent 13F ...
Gateway - Quartz
Quartz· 4 days agoOnly 22% U.S. adults have received an updated COVID-19 vaccine, according to the Centers for Disease Control and Prevention. Moderna says it managed to ...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 2 days agoFurther, Moderna confirmed it's in discussions with the U.S. government to move forward with its...
Novavax Seeks FDA Nod for Updated COVID-19 Vaccine - Novavax (NASDAQ:NVAX), Moderna (NASDAQ:MRNA)
Benzinga· 4 days agoNovavax's filing is based on guidance from the FDA issued last week, which advised COVID-19 vaccine...
The FDA Now Wants Fall COVID Vaccines to Target KP.2—But Not All Manufacturers Can Pivot
Verywell Health via Yahoo News· 2 days agoLess than a week after telling COVID-19 vaccine manufacturers to target the JN.1 variant this fall,...
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines | Investing.com
Investing.com· 5 days agoStocks Analysis by MarketBeat.com (Jea Yu) covering: Merck & Company Inc, Amgen Inc, Biogen Inc,...
Moderna shares rise as Argus lifts price target to $150 By Investing.com
Investing.com· 2 days agoThe firm's decision follows the U.S. Food and Drug Administration's (FDA) approval of Moderna's...
Moderna stock is lone omen of bird flu pandemic
Reuters· 5 days agoThe recent rise of Moderna’s stock tells a grim tale. The $56 billion company which pioneered a Covid vaccine has seen its market value rise 40% since...